Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CCR9 | P51686 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30410070 | 1.00 | UHRF1 (0.46) | UHRF1ALDH1A1HSD17B10TDP1SMARCA2 | |
| SCHEMBL13801171 | 0.81 | UHRF1 (0.48) | UHRF1CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL14317797 | 0.79 | CA1 (0.46) | UHRF1MAPT | |
| SCHEMBL3466579 | 0.79 | UHRF1 (0.46) | UHRF1ALDH1A1HSD17B10TDP1SMARCA2 | |
| SCHEMBL724036 | 0.78 | TDP1 (0.46) | ALDH1A1HSD17B10TDP1SMARCA2SMARCA4 | |
| SCHEMBL26308907 | 0.78 | UHRF1 (0.45) | UHRF1ALDH1A1CYP2D6PSEN1PSEN2 | |
| SCHEMBL25463208 | 0.76 | LMNA (0.50) | UHRF1ALDH1A1CYP2D6PSEN1PSEN2 | |
| SCHEMBL21187203 | 0.76 | UHRF1 (0.52) | UHRF1SMARCA2SMARCA4CYP2D6PSEN1 | |
| SCHEMBL19928748 | 0.75 | ALDH1A1 (0.43) | ALDH1A1HSD17B10TDP1SMARCA2SMARCA4 | |
| SCHEMBL25272109 | 0.75 | LOX (0.44) | ALDH1A1HSD17B10TDP1CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-4436661-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023094827-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-2094670-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008056150-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008056150-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
| EP-1265858-B1 | HYDROGEN REDUCTION OF SULFONYL CHLORIDES TO THIOLS | DU PONT (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6667421-B2 | Hydrogenating an aryl sulfonyl chloride with hydrogen in a solvent in the presence of a palladium catalyst and a base whose conjugate acid pka is >/=2 | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-12-23 | — | — | US | disclosed |
| US-20030055290-A1 | Hydrogen reduction of sulfonyl chlorides to thiols | THE TEXAS A&M UNIVERSITY SYSTEM | 2003-03-20 | — | — | US | disclosed |
| EP-1265858-A1 | HYDROGEN REDUCTION OF SULFONYL CHLORIDES TO THIOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001066517-A1 | HYDROGEN REDUCTION OF SULFONYL CHLORIDES TO THIOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | EDF1, ERLIN1, ECE1 | UHRF1 3544/4885ALDH1A1 1056/4885HSD17B10 2442/4885 |
| US-20030055290-A1 | Hydrogen reduction of sulfonyl chlorides to thiols | TST, IAPP, CBS | UHRF1 3639/4885ALDH1A1 933/4885HSD17B10 1872/4885 |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | CACNA1A, CACNA1E, CACNA1S | UHRF1 4402/4885ALDH1A1 2756/4885HSD17B10 4042/4885 |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, PPM1D | UHRF1 2067/4885ALDH1A1 2592/4885HSD17B10 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.